You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Harvard Business School
Dow
Moodys
Johnson and Johnson

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Patent: 10,400,284

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,400,284
Title:Method for predicting responsiveness to a treatment with an EGFR inhibitor
Abstract: The present invention relates to a method for predicting whether a patient with a cancer is likely to respond to an epidermal growth factor receptor (EGFR) inhibitor, which method comprises determining the expression level hsa-miR-31-3p miRNA in a sample of said patient. The invention also relates to therapeutic uses of an EGFR inhibitor in a patient predicted to respond to said EGFR inhibitor.
Inventor(s): Rio Frio; Thomas (Paris, FR), Laurent-Puig; Pierre (Meudon, FR), Imbeaud; Sandrine (Vitry sur Seine, FR)
Assignee: INTEGRAGEN (Evry, FR) INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (Paris, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (Paris, FR) ASSISTANCE PUBLIQUE--HOPITAUX DE PARIS (Paris, FR) UNIVERSITE PARIS DESCARTES (Paris, FR)
Application Number:14/360,311
Patent Claims:see list of patent claims

Details for Patent 10,400,284

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial INTEGRAGEN (Evry, FR) INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (Paris, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (Paris, FR) ASSISTANCE PUBLIQUE--HOPITAUX DE PARIS (Paris, FR) UNIVERSITE PARIS DE 2031-11-25 RX Orphan search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 001 2006-09-27   Start Trial INTEGRAGEN (Evry, FR) INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (Paris, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (Paris, FR) ASSISTANCE PUBLIQUE--HOPITAUX DE PARIS (Paris, FR) UNIVERSITE PARIS DE 2031-11-25 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 002 2006-09-27   Start Trial INTEGRAGEN (Evry, FR) INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (Paris, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (Paris, FR) ASSISTANCE PUBLIQUE--HOPITAUX DE PARIS (Paris, FR) UNIVERSITE PARIS DE 2031-11-25 RX search
Amgen VECTIBIX panitumumab INJECTABLE; IV (INFUSION) 125147 003 2006-09-27   Start Trial INTEGRAGEN (Evry, FR) INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (Paris, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (Paris, FR) ASSISTANCE PUBLIQUE--HOPITAUX DE PARIS (Paris, FR) UNIVERSITE PARIS DE 2031-11-25 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Medtronic
AstraZeneca
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.